Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176991 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
A Phase 1 study, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04176991: Completed Phase 1 study, sponsored by Larimar Therapeutics.
NCT04176991 is a Phase 1 study that has completed, run by Larimar Therapeutics. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04176991, a Phase 1 study, has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia
Primary Outcome
Overall summary of the Participants with Treatment Emergent Adverse Events
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CTI-1601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-12-11 |
| Est. Completion | 2020-10-31 |
| Phase | Phase 1 |
What the finished NCT04176991 record still lists
NCT04176991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04176991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04176991 about?
NCT04176991 is a clinical study titled "Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia". To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia
What is the current status of trial NCT04176991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-12-11. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT04176991?
The interventions under investigation include: Placebo (BIOLOGICAL), CTI-1601 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04176991?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04176991's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI